Literature DB >> 24102263

Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia.

Pablo B Nery1, Brian A Mc Ardle, Calum J Redpath, Eugene Leung, Robert Lemery, Robert Dekemp, Jim Yang, Arieh Keren, Rob S Beanlands, David H Birnie.   

Abstract

INTRODUCTION: Sarcoidosis is a granulomatous disease of unknown etiology, which involves the heart in 5-25% of cases. Although ventricular tachycardia (VT) has been reported as the first presentation of sarcoidosis, its prevalence has not previously been investigated. In this prospective study, we sought to systematically investigate the prevalence of cardiac sarcoidosis (CS) in patients presenting with monomorphic VT (MMVT) and no previous history of sarcoidosis.
METHODS: Consecutive patients presenting with MMVT to a tertiary care center were screened for inclusion. Patients with idiopathic VT, VT secondary to coronary artery disease, or prior diagnosis of sarcoidosis were excluded. Included patients underwent F-18-fluorodeoxyglucose positron emission tomography (PET) scan. In subjects with PET scanning suggestive of active myocardial inflammation, histological diagnosis was confirmed through extracardiac or endomyocardial biopsy (EMB).
RESULTS: A total of 182 patients presented to our institution with VT between February 2010 and September 2012 and 14 subjects met inclusion criteria. Within this group, six of 14 (42%) patients had abnormal PET scans suggesting active myocardial inflammation. Four of the six patients had tissue biopsies that were diagnostic of sarcoidosis; the remaining two patients had guided EMB indicating nonspecific myocarditis. Atrioventricular block was observed in three of four (75%) patients with CS and none in 10 of the others (P = 0.022). Three of the four patients had pulmonary sarcoidosis and one patient had isolated CS. All four patients were treated with corticosteroids.
CONCLUSION: In this prospective study, four of 14 (28%) patients presenting with MMVT (without idiopathic VT, ischemic VT, or known sarcoidosis) had CS as the underlying etiology. Clinicians should consider screening for CS in patients with unexplained MMVT. ©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  FDG PET; atrioventricular block; cardiac sarcoidosis; ventricular tachycardia

Mesh:

Year:  2013        PMID: 24102263     DOI: 10.1111/pace.12277

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  20 in total

1.  Cardiac sarcoidosis: a challenging diagnosis.

Authors:  Maria Vincenza Polito; Stephan Stoebe; Leonard Leifels; Patrick Stumpp; Kilian Solty; Gennaro Galasso; Federico Piscione; Ulrich Laufs; Karin Klingel; Andreas Hagendorff
Journal:  Clin Res Cardiol       Date:  2018-05-18       Impact factor: 5.460

Review 2.  Cardiac sarcoidosis.

Authors:  Matthew M Zipse; William H Sauer
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

Review 3.  Epidemiology of ventricular tachyarrhythmia : Any changes in the past decades?

Authors:  Benjamin Jong-Ming Pang; Martin Stephen Green
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-08

4.  Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.

Authors:  Hiroshi Ohira; David H Birnie; Elena Pena; Jordan Bernick; Brian Mc Ardle; Eugene Leung; George A Wells; Keiichiro Yoshinaga; Ichizo Tsujino; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Masaharu Nishimura; Nagara Tamaki; Alexander Dick; Carole Dennie; Ran Klein; Jennifer Renaud; Robert A deKemp; Terrence D Ruddy; Benjamin J W Chow; Ross Davies; Renee Hessian; Peter Liu; Rob S B Beanlands; Pablo B Nery
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-11       Impact factor: 9.236

5.  Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).

Authors:  David Birnie; Rob S B Beanlands; Pablo Nery; Shawn D Aaron; Daniel A Culver; Robert A DeKemp; Lorne Gula; Andrew Ha; Jeffery S Healey; Yuko Inoue; Mark A Judson; Daniel Juneau; Kengo Kusano; Russell Quinn; Lena Rivard; Mustafa Toma; Amanda Varnava; George Wells; Melissa Wickremasinghe; Jordana Kron
Journal:  Am Heart J       Date:  2019-10-20       Impact factor: 4.749

6.  18F-FDG-PET in Finnish patients with clinical suspicion of cardiac sarcoidosis: Female sex and history of atrioventricular block increase the prevalence of positive PET findings.

Authors:  Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Pasi Korkola; Mika Kähönen; Kjell Nikus; Kalle Sipilä
Journal:  J Nucl Cardiol       Date:  2017-06-05       Impact factor: 5.952

7.  The role of nuclear cardiac imaging in risk stratification of sudden cardiac death.

Authors:  Daniel Juneau; Fernanda Erthal; Benjamin J W Chow; Calum Redpath; Terrence D Ruddy; Juhani Knuuti; Rob S Beanlands
Journal:  J Nucl Cardiol       Date:  2016-07-28       Impact factor: 5.952

Review 8.  Isolated cardiac sarcoidosis: A focused review of an under-recognized entity.

Authors:  David R Okada; Paco E Bravo; Tomas Vita; Vikram Agarwal; Michael T Osborne; Viviany R Taqueti; Hicham Skali; Panithaya Chareonthaitawee; Sharmila Dorbala; Garrick Stewart; Marcelo Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2016-09-09       Impact factor: 5.952

Review 9.  Importance Of Delayed Enhanced Cardiac MRI In Idiopathic RVOT-VT: Differentiating Mimics Including Early Stage ARVC And Cardiac Sarcoidosis.

Authors:  Carlos Macias; Keijiro Nakamura; Roderick Tung; Noel G Boyle; Shivkumar Kalyanam; Jason S Bradfield
Journal:  J Atr Fibrillation       Date:  2014-12-31

Review 10.  Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.

Authors:  Nisha A Gilotra; Jan M Griffin; Noelle Pavlovic; Brian A Houston; Jessica Chasler; Colleen Goetz; Jonathan Chrispin; Michelle Sharp; Edward K Kasper; Edward S Chen; Ron Blankstein; Leslie T Cooper; Emer Joyce; Farooq H Sheikh
Journal:  J Card Fail       Date:  2021-07-11       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.